A public, Canadian in vitro diagnostics company has raised more than $3 million from private investors, according to a recent filing with the Securities & Exchage Commission.
Response Biomedical has developed cardiovascular and infectious disease tests based on an immunoassay platform and aims to provide lab quality results.
The RAMP platform can tell physicians whether patients are having a heart attack, whether they have a marker that can help physicians to rule out that the patient has deep vein thrombosis or pulmonary embolism. The same technology can also help detect influenza A and B as well as Respiratory Syncytial Virus.
Response Biomedical hopes to raise a total of $4 million. The company has a U.S. subsidiary named Response Point of Care and in the U.S. the tests are carried out in a lab setting. It has offices in Orlando and Shanghai, China to take advantage of global opportunities.
Leveraging global opportunities for in vitro diagnostic companies and navigating the regulatory landscape in BRIC countries is a topic of discussion at the IVD Business Strategy Conference hosted by MD+DI's publisher in San Diego, Nov.6-8.
[Photo Credit: iStockphoto.com user AlexSava]